HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aveda receives second “Proggy”

This article was originally published in The Rose Sheet

Executive Summary

People for the Ethical Treatment of Animals (PETA) awards plant-derived personal-care brand the 2008 PETA Progress (Proggy) Award for "Best Cruelty-Free Spa Products." Aveda's 2008 spa and professional product launches included Green Science skin care, the firm notes. PETA's Proggy Awards recognize animal-friendly achievements in seven categories, including clothing and accessories, food, science and personal-care products; the awards are in their sixth year. In 2004, Aveda was honored for its "Best Cruelty-Free Personal-Care Products." For 30 years, Aveda has focused on offering consumers "the highest quality products and services that have the least environmental impact," says Chuck Bennett, vice president of earth & community care. "This singular mission guides all business decisions at Aveda and inspires us to become better stewards of the Earth," he adds. Estee Lauder, which owns the Aveda and Origins brands, was cited in 2007 at the Personal Care Product Council's annual meeting as having one of the leading corporate responsibility programs in the personal-care industry (1"The Rose Sheet" March 26, 2007, p. 6)

You may also be interested in...

Everybody Wins: Corporate Responsibility Programs That Also “Sell Soap”

Personal care companies increasingly are developing programs that not only reduce their impact on the environment and give back to the local and global community, but award benefits to the business as well, according to Jennifer Nash, executive director of the corporate responsibility initiative at Harvard University's John F. Kennedy School of Government

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts